Download MendeleyStructure-Guided Rescaffolding of Selective Antagonists of BCL-XL.
Koehler, M.F., Bergeron, P., Choo, E.F., Lau, K., Ndubaku, C., Dudley, D., Gibbons, P., Sleebs, B.E., Rye, C.S., Nikolakopoulos, G., Bui, C., Kulasegaram, S., Kersten, W.J., Smith, B.J., Czabotar, P.E., Colman, P.M., Huang, D.C., Baell, J.B., Watson, K.G., Hasvold, L., Tao, Z.F., Wang, L., Souers, A.J., Elmore, S.W., Flygare, J.A., Fairbrother, W.J., Lessene, G.(2014) ACS Med Chem Lett 5: 662-667
- PubMed: 24944740
- DOI: https://doi.org/10.1021/ml500030p
- Primary Citation of Related Structures:
4TUH - PubMed Abstract:
Because of the promise of BCL-2 antagonists in combating chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), interest in additional selective antagonists of antiapoptotic proteins has grown. Beginning with a series of selective, potent BCL-XL antagonists containing an undesirable hydrazone functionality, in silico design and X-ray crystallography were utilized to develop alternative scaffolds that retained the selectivity and potency of the starting compounds.
Organizational Affiliation:
Departments of Discovery Chemistry, Drug Metabolism and Pharmacokinetics, and Early Discovery Biochemistry, Genentech, Inc. , 1 DNA Way, South San Francisco, California 94080, United States.
